GLP-1 agonist
Also written as: GLP-1 — Glucagon-like peptide-1
Glucose-dependent insulinotropic medication that mimics incretin hormones.
Full Definition
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of antidiabetic medications that mimic the action of endogenous incretin hormones. These agents stimulate insulin secretion in a glucose-dependent manner, suppress glucagon release, slow gastric emptying, and promote satiety, leading to improved glycemic control and often significant weight loss. GLP-1 agonists have demonstrated cardiovascular and renal protective effects beyond glucose lowering, making them preferred agents in patients with established cardiovascular disease or chronic kidney disease.
Usage
Usage note: Use hyphens in 'GLP-1' and when used as compound modifier.
In Context
- "Weekly GLP-1 agonist therapy resulted in a mean HbA1c reduction of 1.4% over 26 weeks." — Clinical trial summary
- "The cardiovascular benefits of GLP-1 agonists extend beyond their glucose-lowering effects." — Treatment guideline